



## Lipid-based nanoformulations for peptide delivery

Submitted by Laurent Lemaire on Wed, 03/23/2016 - 16:34

Titre	Lipid-based nanoformulations for peptide delivery
Type de publication	Article de revue
Auteur	Matougui, Nada [1], Boge, Lukas [2], Groo, Anne-Claire [3], Umerska, Anita [4], Ringstad, Lovisa [5], Bysell, Helena [6], Saulnier, Patrick [7]
Pays	Pays-Bas
Editeur	Elsevier
Type	Article scientifique dans une revue à comité de lecture
Année	2016
Langue	Anglais
Date	11 Avril 2016
Pagination	80-97
Volume	502
Section	1-2
Titre de la revue	International Journal of Pharmaceutics
ISSN	1873-3476
Mots-clés	drug delivery [8], Lipids [9], Nanoformulations [10], Peptides [11]
Résumé en anglais	<p>Nanoformulations have attracted a lot of attention because of their size-dependent properties. Among the array of nanoformulations, lipid nanoformulations (LNFs) have evoked increasing interest because of the advantages of their high degree of biocompatibility and versatility. The performance of lipid nanoformulations is greatly influenced by their composition and structure. Therapeutic peptides represent a growing share of the pharmaceutical market. However, the main challenge for their development into commercial products is their inherent physicochemical and biological instability. Important peptides such as insulin, calcitonin and cyclosporin A have been incorporated into LNFs. The association or encapsulation of peptides within lipid-based carriers has shown to protect the labile molecules against enzymatic degradation. This review describes strategies used for the formulation of peptides and some methods used for the assessment of association efficiency. The advantages and drawbacks of such carriers are also described.</p>
URL de la notice	<a href="http://okina.univ-angers.fr/publications/ua14547">http://okina.univ-angers.fr/publications/ua14547</a> [12]
DOI	10.1016/j.ijpharm.2016.02.019 [13]
Autre titre	Int J Pharm
Identifiant (ID) PubMed	26899976 [14]

---

### Liens

[1] <http://okina.univ-angers.fr/nada.matougui/publications>

- [2] [http://okina.univ-angers.fr/publications?f\[author\]=24558](http://okina.univ-angers.fr/publications?f[author]=24558)
- [3] [http://okina.univ-angers.fr/publications?f\[author\]=24559](http://okina.univ-angers.fr/publications?f[author]=24559)
- [4] <http://okina.univ-angers.fr/anita.umerska/publications>
- [5] [http://okina.univ-angers.fr/publications?f\[author\]=24561](http://okina.univ-angers.fr/publications?f[author]=24561)
- [6] [http://okina.univ-angers.fr/publications?f\[author\]=24562](http://okina.univ-angers.fr/publications?f[author]=24562)
- [7] <http://okina.univ-angers.fr/patrick.saulnier/publications>
- [8] [http://okina.univ-angers.fr/publications?f\[keyword\]=7225](http://okina.univ-angers.fr/publications?f[keyword]=7225)
- [9] [http://okina.univ-angers.fr/publications?f\[keyword\]=1146](http://okina.univ-angers.fr/publications?f[keyword]=1146)
- [10] [http://okina.univ-angers.fr/publications?f\[keyword\]=20816](http://okina.univ-angers.fr/publications?f[keyword]=20816)
- [11] [http://okina.univ-angers.fr/publications?f\[keyword\]=4952](http://okina.univ-angers.fr/publications?f[keyword]=4952)
- [12] <http://okina.univ-angers.fr/publications/ua14547>
- [13] <http://dx.doi.org/10.1016/j.ijpharm.2016.02.019>
- [14] <http://www.ncbi.nlm.nih.gov/pubmed/26899976?dopt=Abstract>

Publié sur *Okina* (<http://okina.univ-angers.fr>)